NAD+ peptide and NAD+ injections: benefits, dosage, side effects and the evidence

NAD+ is short for nicotinamide adenine dinucleotide. It is a coenzyme that carries electrons in the reactions cells use to turn food into energy, and it is also consumed by enzymes that repair DNA and regulate genes, including the sirtuins, the PARP enzymes and CD38 ^[1]. Every cell makes it, mostly by recycling nicotinamide, a form of vitamin B3.

People search for the NAD+ peptide, NAD peptide or NAD plus peptide, but the name is a misnomer. The product sold in peptide shops is the same molecule the body makes, supplied as a freeze-dried powder. It is listed on PepFinder because the same stores that sell research peptides sell it, often in the same vial format, and because buyers compare its price and testing in the same way.

Interest in NAD+ comes from ageing research. Levels fall with age in the tissues of rodents and people, and in animals, raising NAD+ has improved many age-related measures ^[1][2]. Whether taking NAD+ or its precursors does the same in people is a separate question, and the human evidence so far is much thinner than the animal work.

No. A peptide is a short chain of amino acids joined by peptide bonds. NAD+ contains no amino acids at all: it is two nucleotides, one carrying nicotinamide and one carrying adenine, linked through their phosphate groups. It belongs with vitamins and nucleotides, not with peptides such as MOTS-c or SS-31.

So when people ask whether NAD+ is a peptide, the short answer is that it is not, even though it is marketed next to them. The same applies to 5-amino-1MQ, a small molecule sold by peptide stores. By contrast, glutathione really is a peptide, although a very small one of three amino acids.

NAD+ has two broad jobs. In energy metabolism it shuttles between an oxidised form (NAD+) and a reduced form (NADH), carrying electrons from the breakdown of glucose and fat to the mitochondria, where they drive ATP production. It is also used up as a raw material by signalling enzymes: sirtuins use it to remove chemical tags from proteins, PARPs use it to repair DNA, and CD38 breaks it down in immune cells ^[1].

Because these enzymes consume NAD+, anything that increases their activity drains the pool. In human skin samples from people aged from newborn to 77, NAD+ levels fell with age in both men and women, and in men this tracked with rising DNA damage and higher PARP activity ^[3]. Reviews of the field link the age-related decline to metabolic disease, frailty and cognitive decline in animal models, while stressing that it is still not known whether restoring NAD+ is safe or beneficial in ageing humans ^[1].

A NAD injection is NAD+ dissolved in sterile liquid and given by needle. Wellness clinics mainly give it as a slow intravenous drip. Peptide stores sell freeze-dried vials, often labelled 500 mg or 1,000 mg, which buyers mix with water and inject under the skin, and some sell ready-made pens or nasal sprays.

The NAD injection, NAD+ injection and NAD plus injection that people search for all refer to the same molecule. What differs is the route, the speed of delivery and the quality of the product, which for research-labelled vials depends entirely on the manufacturer.

Most claims about NAD peptide benefits, such as more energy, better focus, anti-ageing effects and faster recovery, come from animal studies of NAD+ precursors or from the biology of the molecule, not from trials of NAD+ injections. A 2018 review of the in vivo evidence found that NAD-boosting molecules improved a wide range of conditions in rodents, including metabolic, muscle, heart and brain disorders ^[2].

Human evidence is weaker. A 2026 systematic review found 33 human intervention studies of NAD-related compounds published between 2010 and October 2025. Oral NR and NMN reliably raised NAD-related metabolites and were generally well tolerated, but effects on function, metabolism, blood vessels and other healthspan measures were mixed and often null. The review found no eligible outcome trial of intravenous or intramuscular NAD+ itself ^[6].

A separate 2026 review of intravenous longevity therapies, including NAD+ and glutathione drips, reached a similar view: small studies report short-term changes in oxidative stress markers and some modest improvements in fatigue, placebo-controlled trials are scarce, and the authors described IV longevity therapy as experimental rather than evidence-based ^[7].

The first study of what happens to infused NAD+ in people was published in 2019. Eight healthy men received 750 mg of NAD+ by intravenous drip over six hours, and three received saline. Surprisingly, blood NAD+ did not rise for the first two hours, suggesting the body cleared it rapidly, and only reached about four times baseline at six hours. Breakdown products and some intact NAD+ appeared in the urine. No adverse events were seen in this small group ^[4].

A 2026 retrospective study from a commercial clinic chain compared records of clients given 500 mg of NAD+ or of the precursor NR by drip on four consecutive days. Neither group showed changes in liver, kidney, thyroid or inflammation markers over 30 days. HDL cholesterol fell in the NAD+ group and HbA1c fell in the NR group, but these were exploratory findings without a placebo group, and the authors were employed by the clinic company ^[5].

One case series looked at NAD+ drips in addiction. Fifty people with substance use disorder given infusions of NAD+ combined with an enkephalinase-inhibiting amino acid formula reported lower craving, anxiety and depression scores than at baseline. There was no control group, and the lead author holds patents on the amino-acid therapy ^[15]. The authors themselves called for placebo-controlled trials. So the NAD+ injection benefits claimed online have not yet been tested in the kind of trial that could confirm them.

People ask what NAD+ peptide is used for, and what NAD+ peptide does, in several specific areas. The evidence differs for each.

Energy and fatigue. The best-studied product here is not NAD+ but NADH, its reduced form, taken by mouth with coenzyme Q10. In a 12-week trial in 207 people with ME/CFS, the group given 200 mg CoQ10 plus 20 mg NADH daily reported less cognitive fatigue and better quality of life than at the start of the study ^[19]. A 2024 systematic review of 10 randomised trials of NAD and NADH found them well tolerated, with the most common side effects being muscle pain, fatigue, sleep disturbance and headache ^[8]. Neither shows that injected NAD+ reduces fatigue.

Metabolism and insulin sensitivity. In a 10-week randomised trial in 25 postmenopausal women with prediabetes and overweight or obesity, 250 mg a day of the precursor NMN increased muscle insulin sensitivity and insulin signalling, measured with the clamp technique, compared with placebo ^[11]. In 80 healthy middle-aged adults, 300 to 900 mg of NMN daily for 60 days raised blood NAD levels and improved six-minute walking distance, but did not change the HOMA-IR insulin resistance score ^[13].

Brain and Parkinson's disease. In the NADPARK phase 1 trial, 30 people newly diagnosed with Parkinson's disease took 1,000 mg of NR or placebo for 30 days. NR was well tolerated and raised brain NAD levels, measured by magnetic resonance spectroscopy, although by varying amounts. People whose brain levels rose showed changes in brain metabolism and mild clinical improvement, and the authors called for larger trials ^[14].

Blood pressure and arteries. In a six-week crossover trial in healthy middle-aged and older adults, NR at 1,000 mg a day was well tolerated and raised NAD+ metabolism; the authors suggested further trials of its effects on blood pressure and arterial stiffness ^[10].

Ageing and longevity. No human trial has shown that NAD+ or its precursors slow ageing or extend life. The 2021 Nature Reviews paper on NAD+ and ageing lists safety and benefit in ageing humans as open questions ^[1].

The NAD supplement vs injection question is really about precursors versus the whole molecule. Many oral supplements do not contain NAD+ itself but its building blocks: nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). These are small enough to be absorbed and converted into NAD+ inside cells.

Oral precursors have the stronger human evidence for raising NAD+. In the first human pharmacokinetic trial of NR, single doses of 100, 300 and 1,000 mg produced dose-dependent increases in the blood NAD+ metabolome, and in one volunteer blood NAD+ rose up to 2.7-fold after a single dose ^[9]. Single oral doses of 100, 250 and 500 mg of NMN in 10 healthy Japanese men caused no significant symptoms or changes in heart rate, blood pressure or temperature ^[12].

Injected NAD+ reaches the blood directly, but the 2019 infusion study suggests it is broken down quickly, with most of the early dose cleared before blood levels began to rise ^[4]. No published study has compared an NAD+ injection with an oral NR or NMN supplement in the same people, so there is no evidence that injections work better. The 2026 systematic review concluded that clinical effectiveness for anti-ageing and wellness outcomes remains inconclusive for all routes ^[6].

NMN is the immediate precursor of NAD+ in the recycling pathway cells use to make it, and its availability limits how fast NAD+ is made ^[11]. NR feeds into the same pathway. NAD+ itself is a larger molecule. In the infusion study, the pattern of breakdown products in blood pointed to enzymes that cut NAD+ apart, and blood levels rose only after a delay ^[4].

In practical terms the difference is evidence. NMN and NR have randomised, placebo-controlled human trials measuring NAD levels and some clinical outcomes ^{[10][11][13][14]}. NAD+ injections have a pharmacokinetic pilot and a retrospective clinic review ^[4][5]. The 2026 systematic review describes the clinical effects of the precursors as heterogeneous and often null ^[6].

The 2026 clinic study is the only direct comparison of NAD+ and NR by drip. People given NAD+ reported moderate to severe stomach symptoms, a faster heart rate and chest pressure during the drip, which slowed infusions to an average of 97 minutes, while those given NR had milder tingling and cramping and averaged 37 minutes ^[5].

Some stores sell NAD+ nasal sprays as an alternative to needles. We found no published study, in people or animals, that measured how much NAD+ from a nasal spray reaches the blood or the brain, and no trial of its effects. The NAD+ nasal spray vs injection comparison therefore cannot be answered from research: injections have limited pharmacokinetic data, and nasal sprays have none that we could find.

Peptide-store vials are usually intended for NAD+ subcutaneous injection, into the fat under the skin, rather than a drip. We found no published human study of subcutaneous NAD+ that reported blood levels, dose-response or safety. The published human data are for intravenous drips ^[4][5].

The closest evidence is from animals. A 2026 set of standardised safety studies gave NAD+ by intramuscular injection to rats for four weeks at 10 to 100 mg/kg a day and found no toxic effects at the highest dose, apart from local injection-site and nerve lesions that reversed. In separate tests, 10 and 30 mg/kg raised heart rate and lowered blood pressure in rats, while 3 mg/kg did not ^[16]. Animal doses cannot be converted into human doses.

PepFinder does not recommend any dose. The figures below are doses researchers used, with their route.

Intravenous NAD+: 750 mg over six hours in eight healthy men ^[4]; 500 mg a day on four consecutive days in a clinic setting ^[5]. The 2019 authors described 750 mg over six hours as a typical clinical regimen at the time, but it was not tested against other doses.

Oral precursors: NR at 100, 300 and 1,000 mg as single doses ^[9] and 1,000 mg a day for six weeks ^[10] or 30 days ^[14]; NMN at 250 mg a day for 10 weeks ^[11], and 300, 600 or 900 mg a day for 60 days, with blood NAD highest in the 600 and 900 mg groups ^[13]. Oral NADH: 20 mg a day with CoQ10 for 12 weeks ^[19].

No trial has established a NAD+ peptide dosage for subcutaneous injection, so the NAD+ injection dosage chart, per-day, per-week, 500 mg and 1,000 mg charts circulating online are not drawn from published human research. The same applies to a NAD+ injection dosage and frequency or a subcutaneous protocol: no study has compared schedules.

A NAD+ injection dosage calculator only does division, and questions such as the NAD+ injection dosage chart in ml are arithmetic rather than dosing. A 500 mg vial dissolved in 5 mL of liquid contains 100 mg per mL. On a U-100 insulin syringe, which holds 100 units per mL, each unit then holds 1 mg. A 1,000 mg vial in 10 mL is also 100 mg per mL; the same vial in 5 mL is 200 mg per mL, or 2 mg per unit.

Our NAD+ reconstitution calculator does this sum for any vial size and volume, and our guide to bacteriostatic water explains the diluent usually used. Neither is a recommendation to inject anything.

The side effects people report with NAD injection drips are mainly linked to speed. In the 2026 clinic comparison, NAD+ drips caused moderate to severe gastrointestinal symptoms, a raised heart rate and chest pressure, all of which resolved once the infusion ended, and infusions had to be slowed ^[5]. In the 2019 study, a slow six-hour drip of 750 mg caused no adverse events in eight men ^[4]. These studies are small and short.

Flushing is often listed among NAD peptide side effects. It is best documented for nicotinic acid (niacin), a different form of vitamin B3, which causes flushing by acting on a skin receptor. In the six-week NR trial, three participants reported flushing, but two of them were taking placebo ^[10]. We found no controlled study measuring flushing after NAD+ injections.

For oral NAD and NADH, a systematic review of 10 randomised trials reported muscle pain, nervous-system complaints, fatigue, sleep disturbance and headache as the most common side effects, none of which posed a serious risk to participants ^[8]. In the NMN dose-ranging trial, no safety issues were found at up to 900 mg a day for 60 days ^[13].

Long-term safety of NAD+ injections has not been studied. Research-labelled vials add risks unrelated to NAD+ itself: wrong content, bacterial contamination and endotoxins. Our guide to third-party peptide testing explains what an independent test can and cannot confirm.

There is no human answer for injections, because no controlled trial has measured an outcome over time. For blood levels, an intravenous drip took more than two hours to raise plasma NAD+ and peaked at the end of a six-hour infusion ^[4]. Oral NR raised blood NAD+ within hours of a single dose ^[9], and in the NMN trial blood NAD was raised at the first check at 30 days ^[13].

Clinical effects in precursor trials were measured after 30 days to 10 weeks ^[11][13][14]. Reports of feeling different within hours of a drip are not tested against placebo.

NAD+ is often sold in bundles with MOTS-c and 5-amino-1MQ. No published study has tested NAD+ together with either, in people or animals, so there is no evidence that the combinations add to each other, and no research basis for a combined dose.

The link people draw with 5-amino-1MQ is biochemical. 5-amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that uses up nicotinamide. In fat cells in the laboratory, NNMT inhibitors increased NAD+ inside the cells, and in obese mice on a high-fat diet, a potent NNMT inhibitor reduced body weight and white fat without changing food intake ^[17]. The 5-amino-1MQ guide covers this in detail.

MOTS-c is a mitochondrial peptide that acts through the energy sensor AMPK, a different mechanism from NAD+. The same goes for other metabolic compounds sold by the same stores, such as SLU-PP-332. Some wellness clinics also combine NAD+ drips with glutathione; no study of that pairing was found either.

Searches for the best NAD+ injection usually mean the best-quality product. There is no licensed NAD+ injection to use as a benchmark, so quality comes down to identity, purity, content and sterility. A certificate of analysis should show the tested amount per vial and purity by HPLC, and ideally endotoxin and sterility results. See how to read a COA.

NAD+ vials are supplied as freeze-dried powder, like peptides. The usual practice is to keep unopened vials cold, dry and away from light and to refrigerate after mixing; see how to store peptides.

In Canada, Health Canada's April 2026 advisory on peptides bought online named NAD+ among the unauthorised products it had seized, stated that unauthorised drug products are illegal in Canada, and said that research-use-only labelling does not make them legal ^[18]. See our Canada legal status page.

Oral NR and NMN are sold as food supplements in many countries, but their status varies by country and changes over time; we have not verified it market by market. For NAD+ vials and nasal sprays in the UK, US, Australia and New Zealand, see the relevant pages under legal status.

PepFinder does not sell NAD+. To compare vial prices, see NAD+ prices. For country searches such as NAD+ peptide UK or NAD+ peptide Australia, compare NAD+ suppliers in the UK and NAD+ prices in Australia, but check the local rules first. Australia regulates peptide-store products as therapeutic goods.

Our list of third-party tested suppliers shows which vendors publish independent results, and how to spot a fake peptide supplier covers warning signs. How we rate vendors is set out in our methodology.